We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

49 hedge funds and large institutions have $141M invested in AVEO Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,723% more call options, than puts

Call options by funds: $1.6M | Put options by funds: $88K

326% more capital invested

Capital invested by funds: $33.2M → $141M (+$108M)

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0% more funds holding

Funds holding: 49 → 49 (0)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

Holders
49
Holders Change
–
Holders Change %
0%
% of All Funds
1.22%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
15
Increased
9
Reduced
10
Closed
14
Calls
$1.6M
Puts
$88K
Net Calls
+$1.52M
Net Calls Change
+$1.51M

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$6.64M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.36M
3
ACA
Avoro Capital Advisors
New York
+$2.12M
4
Millennium Management
Millennium Management
New York
+$1M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$915K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$2.52M
2
GTC
Ghost Tree Capital
New York
-$885K
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$872K
4
NLVP
New Leaf Venture Partners
New York
-$787K
5
SCM
Sarissa Capital Management
Connecticut
-$598K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$36.3M – – –
RCM
2
RA Capital Management
Massachusetts
$18.7M +$6.64M +843,558 New
ACA
3
Avoro Capital Advisors
New York
$14.7M +$2.12M +269,442 +68%
PA
4
Perceptive Advisors
New York
$13.3M +$710K +90,185 +18%
Vanguard Group
5
Vanguard Group
Pennsylvania
$7.88M +$915K +116,223 +49%
6CM
6
683 Capital Management
New York
$7.42M +$40.7K +5,175 +2%
NLVP
7
New Leaf Venture Partners
New York
$6.86M -$787K -100,000 -24%
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$6.66M +$2.36M +300,000 New
Renaissance Technologies
9
Renaissance Technologies
New York
$5.22M -$276K -35,100 -13%
SFM
10
Sphera Funds Management
Israel
$4.88M -$551K -70,000 -24%
BlackRock
11
BlackRock
New York
$4.15M -$87.9K -11,167 -6%
AC
12
Armistice Capital
New York
$3.55M -$2.52M -320,000 -67%
Millennium Management
13
Millennium Management
New York
$2.89M +$1M +127,157 +4,072%
EI
14
EAM Investors
California
$1.98M +$702K +89,163 New
DVC
15
Deer VI & Co
New York
$1.5M – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.33M +$224K +28,446 +90%
BCM
17
Bridgeway Capital Management
Texas
$1.02M – – –
EWM
18
Evercore Wealth Management
New York
$374K – – –
PP
19
Paloma Partners
Connecticut
$337K -$126K -16,056 -51%
CHAM
20
Clear Harbor Asset Management
Connecticut
$289K +$78.7K +10,000 New
Northern Trust
21
Northern Trust
Illinois
$259K – – –
CC
22
Cannell & Co
New York
$244K +$16.1K +2,050 +23%
PVI
23
Pura Vida Investments
New York
$222K +$78.7K +10,000 New
Jane Street
24
Jane Street
New York
$184K +$65.1K +8,269 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$164K -$9.33K -1,185 -14%
1
2 3

AVEO Hedge Fund Activity: Q2 2017 in Review

49 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2017, worth a combined $141M — up 326% from $33.2M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new AVEO positions and 14 closed out — a net gain of 1 holder — while 9 added to existing stakes and 10 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $6.64M. The largest seller was Armistice Capital, cutting an estimated $2.52M.

  • 49 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $141M of AVEO Pharmaceuticals, Inc. stock for Q2 2017, up 326% quarter-over-quarter.
  • 15 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2017 and 14 closed out, a net change of +1 holder.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2017 was RA Capital Management, an estimated $6.64M added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q2 2017 was Armistice Capital, an estimated $2.52M sold.

Based on aggregated 13F filings for Q2 2017.